Richard David Wainford

Richard David Wainford

Auto-generated profile, based on publicly available information

Richard David Wainford

Emory University School of Medicine

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2022 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
Aletta SchutteAletta Schutte
Aletta Schutte
TJTazeen H Jafar
Tazeen H Jafar
NPNeil R Poulter
Neil R Poulter
ADAlbertino Damasceno
Albertino Damasceno
NKNadia A Khan
Nadia A Khan
MTMaciej Tomaszewski
Maciej Tomaszewski
Raised blood pressure (BP) is the leading cause of preventable death in the world. Yet, its global prevalence is increasing, and it remains poorly detected, treated, and controlled in both high- and low-resource settings. From the perspective of members of the International Society of Hypertension based in all regions, we reflect on the past, present, and future of hypertension care, highlighting key challenges and opportunities, which are often region-specific. We report that most countries failed to show sufficient improvements in BP control rates over the past three decades, with greater improvements mainly seen in some high-income countries, also reflected in substantial reductions in the burden of cardiovascular disease and deaths. Globally, there are significant inequities and disparities based on resources, sociodemographic environment, and race with subsequent disproportionate hypertension-related outcomes. Additional unique challenges in specific regions include conflict, wars, migration, unemployment, rapid urbanization, extremely limited funding, pollution, COVID-19-related restrictions and inequalities, obesity, and excessive salt and alcohol intake. Immediate action is needed to address suboptimal hypertension care and related disparities on a global scale. We propose a Global Hypertension Care Taskforce including multiple stakeholders and societies to identify and implement actions in reducing inequities, addressing social, commercial, and environmental determinants, and strengthening health systems implement a well-designed customized quality-of-care improvement framework.

15 January 2015 in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
Verified
Journal Article
Closed access
PDF file
JFJason D. Foss
Jason D. Foss
RWRichard D. Wainford
Richard D. Wainford
WEWilliam C. Engeland
William C. Engeland
GFGregory D. Fink
Gregory D. Fink
JOJohn W. Osborn
John W. Osborn
Renal denervation has been shown to lower arterial pressure in some hypertensive patients, yet it remains unclear whether this is due to ablation of afferent or efferent renal nerves. To investigate the role of afferent renal nerves in arterial pressure regulation, previous studies have used methods that disrupt both renal and nonrenal afferent signaling. The present study was conducted to develop and validate a technique for selective ablation of afferent renal nerves that does not disrupt other afferent pathways. To do this, we adapted a technique for sensory denervation of the adrenal gland by topical application of capsaicin and tested the hypothesis that exposure of the renal nerves to capsaicin (renal-CAP) causes ablation of afferent but not efferent renal nerves. Renal-CAP had no effect on renal content of the efferent nerve markers tyrosine hydroxylase and norepinephrine; however, the afferent nerve marker, calcitonin gene-related peptide was largely depleted from the kidney 10 days after intervention, but returned to roughly half of control levels by 7 wk postintervention. Moreover, renal-CAP abolished the cardiovascular responses to acute pharmacological stimulation of afferent renal nerves. Renal-CAP rats showed normal weight gain, as well as cardiovascular and fluid balance regulation during dietary sodium loading. To some extent, renal-CAP did blunt the bradycardic response and increase the dipsogenic response to increased salt intake. Lastly, renal-CAP significantly attenuated the development of deoxycorticosterone acetate-salt hypertension. These results demonstrate that renal-CAP effectively causes selective ablation of afferent renal nerves in rats.

10 April 2015 in Current Hypertension Reports
Verified
Journal Article
Open access
PDF file
CCCasey Y. Carmichael
Casey Y. Carmichael
RWRichard D. Wainford
Richard D. Wainford
The etiology of hypertension, a critical public health issue affecting one in three US adults, involves the integration of the actions of multiple organ systems, including the central nervous system. Increased activation of the central nervous system, driving enhanced sympathetic outflow and increased blood pressure, has emerged as a major contributor to the pathogenesis of hypertension. The hypothalamus is a key brain site acting to integrate central and peripheral inputs to ultimately impact blood pressure in multiple disease states that evoke hypertension. This review highlights recent advances that have identified novel signal transduction mechanisms within multiple hypothalamic nuclei (e.g., paraventricular nucleus, arcuate nucleus) acting to drive the pathophysiology of hypertension in neurogenic hypertension, angiotensin II hypertension, salt-sensitive hypertension, chronic intermittent hypoxia, and obesity-induced hypertension. Increased understanding of hypothalamic activity in hypertension has the potential to identify novel targets for future therapeutic interventions designed to treat hypertension.

17 May 2022 in Journal of Human Hypertension
Verified
Journal Article
Open access
PDF file
NCNorm Campbell
Norm Campbell
PWPaul K Whelton
Paul K Whelton
MOMarcelo Orias
Marcelo Orias
RWRichard D. Wainford
Richard D. Wainford
Francesco Paolo CappuccioFrancesco Paolo Cappuccio
Francesco Paolo Cappuccio
XZXin-Hua Zhang
Xin-Hua Zhang

1 June 2007 in Peptides
Verified
Journal Article
Closed access
ARAnna Rizzi
Anna Rizzi
BSBarbara Spagnolo
Barbara Spagnolo
RWRichard D. Wainford
Richard D. Wainford
CFCarmela Fischetti
Carmela Fischetti
RGRemo Guerrini
Remo Guerrini
GCGirolamo Calo
Girolamo Calo

1 March 2012 in Endocrinology
Verified
Journal Article
Open access
PDF file
TYTadashi Yoshida
Tadashi Yoshida
LSLaura Semprun-Prieto
Laura Semprun-Prieto
RWRichard D. Wainford
Richard D. Wainford
SSSergiy Sukhanov
Sergiy Sukhanov
DKDaniel R. Kapusta
Daniel R. Kapusta
PDPatrice Delafontaine
Patrice Delafontaine
Angiotensin II (Ang II), which is elevated in many chronic disease states such as end-stage renal disease and congestive heart failure, induces cachexia and skeletal muscle wasting by increasing muscle protein breakdown and reducing food intake. Neurohormonal mechanisms that mediate Ang II-induced appetite suppression are unknown. Consequently, we examined the effect of Ang II on expression of genes regulating appetite. Systemic Ang II (1 μg/kg · min) infusion in FVB mice rapidly reduced hypothalamic expression of neuropeptide Y (Npy) and orexin and decreased food intake at 6 h compared with sham-infused controls but did not change peripheral leptin, ghrelin, adiponectin, glucagon-like peptide, peptide YY, or cholecystokinin levels. These effects were completely blocked by the Ang II type I receptor antagonist candesartan or deletion of Ang II type 1a receptor. Ang II markedly reduced phosphorylation of AMP-activated protein kinase (AMPK), an enzyme that is known to regulate Npy expression. Intracerebroventricular Ang II infusion (50 ng/kg · min) caused a reduction of food intake, and Ang II dose dependently reduced Npy and orexin expression in the hypothalamus cultured ex vivo. The reduction of Npy and orexin in hypothalamic cultures was completely prevented by candesartan or the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleoside. Thus, Ang II type 1a receptor-dependent Ang II signaling reduces food intake by suppressing the hypothalamic expression of Npy and orexin, likely via AMPK dephosphorylation. These findings have major implications for understanding mechanisms of cachexia in chronic disease states such as congestive heart failure and end-stage renal disease, in which the renin-angiotensin system is activated.